Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.

Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Röth A, Kaun S, Thiel E, Korfel A, Weller M.

Neurology. 2012 Aug 28;79(9):890-6. doi: 10.1212/WNL.0b013e318266fcb2. Epub 2012 Aug 15.

PMID:
22895585
2.

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M.

Lancet Oncol. 2010 Nov;11(11):1036-47. doi: 10.1016/S1470-2045(10)70229-1. Epub 2010 Oct 20.

PMID:
20970380
3.

Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.

Blasco H, Senecal D, Le Gouge A, Pinard E, Benz-de Bretagne I, Colombat P, Hulot JS, Chatelut E, Le Guellec C.

Br J Clin Pharmacol. 2010 Sep;70(3):367-75. doi: 10.1111/j.1365-2125.2010.03712.x.

4.

Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.

Omuro AM, DeAngelis LM, Yahalom J, Abrey LE.

Neurology. 2005 Jan 11;64(1):69-74.

PMID:
15642906
5.

Results of treatment of 112 cases of primary CNS lymphoma.

Yamanaka R, Morii K, Shinbo Y, Homma J, Sano M, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Kakuma T, Tanaka R.

Jpn J Clin Oncol. 2008 May;38(5):373-80. doi: 10.1093/jjco/hyn027. Epub 2008 Apr 15.

PMID:
18413337
6.

Therapeutic management of refractory or relapsed primary central nervous system lymphomas.

Reni M, Ferreri AJ.

Ann Hematol. 2001;80 Suppl 3:B113-7. Review.

PMID:
11757691
7.

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.

J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24.

PMID:
16864853
8.

A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.

Taoka K, Okoshi Y, Sakamoto N, Takano S, Matsumura A, Hasegawa Y, Chiba S.

Int J Hematol. 2010 Nov;92(4):617-23. doi: 10.1007/s12185-010-0703-9. Epub 2010 Oct 22.

PMID:
20967518
9.

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I, van Glabbeke M; European Organization for Research and Treatment of Cancer Lymphoma Group.

J Clin Oncol. 2003 Dec 15;21(24):4483-8. Epub 2003 Nov 3.

PMID:
14597741
10.

The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.

Kasenda B, Rehberg M, Thürmann P, Franzem M, Veelken H, Fritsch K, Schorb E, Finke J, Lebiedz D, Illerhaus G.

Ann Hematol. 2012 Aug;91(8):1257-64. doi: 10.1007/s00277-012-1441-2. Epub 2012 Mar 29.

PMID:
22456893
11.
12.

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F.

Eur J Haematol. 2003 Apr;70(4):219-24.

PMID:
12656744
13.

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.

Cheng T, Forsyth P, Chaudhry A, Morris D, Glück S, Russell JA, Stewart DA.

Bone Marrow Transplant. 2003 Apr;31(8):679-85.

PMID:
12692608
14.

Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE.

Cancer. 2010 Oct 1;116(19):4605-12. doi: 10.1002/cncr.25363.

15.

Late relapse in primary central nervous system lymphoma: clonal persistence.

Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM.

Neuro Oncol. 2011 May;13(5):525-9. doi: 10.1093/neuonc/nor014. Epub 2011 Mar 3.

16.

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.

Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M.

Neurology. 2015 Mar 24;84(12):1242-8. doi: 10.1212/WNL.0000000000001395. Epub 2015 Feb 25.

17.

Patterns of treatment in older adults with primary central nervous system lymphoma.

Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE.

Cancer. 2007 Sep 15;110(6):1338-44.

18.

Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial.

Zeremski V, Koehler M, Fischer T, Schalk E.

Ann Hematol. 2016 Apr;95(5):793-9. doi: 10.1007/s00277-016-2602-5. Epub 2016 Jan 23.

PMID:
26801791
19.

[High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].

Usui N, Dobashi N, Yano S, Yahagi Y, Takei Y, Otsubo H, Takahara S, Yamaguchi Y, Saito T, Minami J, Kamiyama Y, Morikawa N, Machishima T, Osawa H, Aiba K.

Gan To Kagaku Ryoho. 2010 Jul;37(7):1277-82. Japanese.

PMID:
20647709
20.

Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.

Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H, Takahashi H, Onda K, Takahashi H, Tanaka R.

Ann Hematol. 2005 Jul;84(7):447-55. Epub 2005 Mar 4.

PMID:
15747120

Supplemental Content

Support Center